Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) had its target price boosted by equities researchers at B. Riley from $20.00 to $24.00 in a note issued to investors on Wednesday ...

March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals ... which developed the FDA-approved CAR T-cell therapy Breyanzi ® for large B-cell lymphoma, until the company was sold to Celgene, now ...